This study reveals for the first time a new mechanism by which ezetimibe acts on TNBC, that is, ezetimibe inhibits the growth of TNBC by inhibiting the activation of the PDGFRβ/AKT pathway, thereby inducing G1 blockade in tumor cells. The gene discussed is AKT1; the disease is neoplasm.